Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636364 | 0.86 | FAAH (0.73) | FAAH | |
| SCHEMBL12509391 | 0.86 | ALDH1A1 (0.59) | FAAHLRRK2ALDH1A1MEN1KMT2A | |
| SCHEMBL12509031 | 0.85 | FAAH (0.51) | FAAHLRRK2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3641747 | 0.80 | FAAH (0.70) | FAAHLMNA | |
| SCHEMBL12509269 | 0.78 | FAAH (0.52) | FAAHF10ALDH1A1MEN1KMT2A | |
| SCHEMBL3636772 | 0.78 | FAAH (0.86) | FAAH | |
| SCHEMBL12509221 | 0.78 | CYP3A4 (0.52) | FAAHCYP3A4CYP2D6CYP2C9GRIN2B | |
| SCHEMBL12509065 | 0.77 | SRD5A2 (0.56) | FAAHLRRK2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12508556 | 0.77 | POLB (0.54) | FAAHF10ALDH1A1MEN1KMT2A | |
| SCHEMBL12509219 | 0.75 | FAAH (0.49) | FAAHCYP3A4CYP2C9F10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | FAAH 1/4885LRRK2 4404/4885CYP3A4 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.